J. Fernando Arevalo, MD, PhD, FACS, FASRS, spoke about a recent study looking at what happens to patients with diabetic retinopathy who are lost to follow-up. He presented this research at the 2024 Retina World Congress meeting in Fort Lauderdale, Florida.
David Almeida, MD, PhD, MBA, shared insights on the surgical tools he uses in his practice at the 2024 Retina World Congress meeting in Fort Lauderdale, Florida.
Dilsher S. Dhoot, MD, shared details about the Week 52 safety and efficacy data from the US phase 1 clinical trial of sustained-release axitinib hydrogel implant (OTX-TKI) for neovascular age-related macular degeneration at the 2024 Retina World Congress meeting in Fort Lauderdale, Florida.
Professor Paulo-Eduardo Stanga spoke with Modern Retina about a new wearable assistance device at the 2024 Retina World Congress meeting held in Fort Lauderdale, Florida
David Eichenbaum, MD, spoke with Modern Retina about the phase 3 trial of sozinibercept at the 2024 Retina World Congress meeting.
Modern Retina spoke with Paulo-Eduardo Stanga, MD, from The Retina Clinic London, London, United Kingdom at the 2024 Retina World Congress meeting.
Christine Kay, MD, spoke with Modern Retina to share insights from her presentation on longitudinal BCVA and safety analysis of mutation-agnostic MCO-010 optogenetic therapy For retinitis pigmentosa
David Almeida, MD, PhD, MBA, presented on gene therapy associated uveitis at the 2024 Retina World Congress meeting in Fort Lauderdale, Florida.
Sunir Garg, MD, FACS, shares strategies to minimize pain with intravitreal injections.
Modern Retina spoke with Veeral Sheth, MD, MBA, FASRS, FACS, at the 2024 Retina World Congress meeting about the PRISM study, 4DMT's gene therapy trial for wet AMD.
Michael A. Singer, MD, shares details about the an IRIS database look at Triamcinolone Acetonide.
Several presentations at Retina World Congress 2024 highlight the importance of diversity equity and inclusion in the retina field.
Several companies working in the retina space have shared that they plan to release data at this year’s meeting in Fort Lauderdale, Florida.
At the ARVO meeting in Seattle, Washington, the Eye Care Network spoke with Giulia Corradetti, MD about AMD.
Barry Kuppermann, MD, PhD, director of the Gavin Herbert Eye Institute at the University of California Irvine, speaks about his ARVO poster presentation
Several presentations will provide research updates on various topics related to retinal vein occlusion (RVO).
As the annual ARVO conference draws closer, more companies have released information on presentations related to their pipeline and new data.
The intent of this extension is to assess potentially greater durability compared to aflibercept and will increase the statistical power of the study.
This initiative will provide a variety of tools to promote awareness and education, including some resources in both English and Spanish.
Akari Therapeutics, Ocuphire Pharma, and PharmAbcine are among the companies that have shared their plans for presentations the ARVO annual conference, being held in Seattle, Washington. More companies are expected to announce their presentations in the coming days.
The Vision Simulator shows disease progression and vision loss simulations for diabetic macular edema, diabetic retinopathy, AMD, XLRP, and achromatopsia.
Rising costs of metabolic agents, particularly those used in the treatment of diabetes, impacts patients and the medical systems, such as Medicare and Medicaid.
Through free, virtual webinars, the companies are working to bring clinical education to eye care professionals around the world.
The program will use OCT images to identify and monitor AMD in its early stages.
The company’s AI technology uses retinal imaging to assess potential health risks in patients.
The company created this new role as they see continued growth and room for more expansion.
The SAB additions include Usha Chakravarthy, MBBS, PhD; Allen Ho, MD, FACS, FASRS, and Frank Holz, MD, FEBO, FAVO.
